EU drugs agency: swine flu vaccine data “promising”

	Tweet

Early clinical trial results suggest that swine flu vaccines now being rushed through development produce a strong immune response, suggesting they should work well, the head of Europe’s drugs watchdog said on Thursday.

“It seems to be quite promising,” Thomas Lonngren, executive director of the European Medicines Agency (EMEA), told reporters.

“The immune response to all these vaccines is a very high response, whatever type of vaccine it is, whether it is adjuvanted or non-adjuvanted,” he added.

Adjuvants are substances added to vaccines to boost their effectiveness.

The EMEA’s expert committee on new medicines will consider the first three H1N1 swine flu vaccines from GlaxoSmithKline , Novartis and Baxter at its next meeting during the week commencing Sept. 21.

If all goes well, the first swine flu vaccines could be licensed by the European Commission early in October, Lonngren said.

LONDON (Reuters)

RELATED STORIES:
Swine Flu vaccination: voluntary system works   ‘Swine Flu Parties’ Or Intentionally Catching H1N1 a Very Bad Idea, Says Expert   Argentina declares animal health emergency over flu   How to Deal with Swine Flu: Heeding the Mistakes of 1976   Next question in swine flu - who gets vaccinated?   Drug resistant H1N1 no major change in virus: WHO   Britain to start swine flu vaccination next week   Deaths not linked to H1N1 vaccines: WHO   Australia approves new swine flu detention powers   Vietnam detects 3 cases of drug-resistant swine flu   New flu hit estimated 10 percent of New Yorkers   H1N1 flu worrying due to its unpredictability: WHO

Comments

[ + Post Your Own ]

Now you're in the public comment zone. What follows is not Armenian Medical Network's stuff; it comes from other people and we don't vouch for it. A reminder: By using this Web site you agree to accept our Terms of Service. Click here to read the Rules of Engagement.

There are no comments for this entry yet. [ + Comment here + ]